Gerald E. Hanks, MD

home / authors / gerald-e-hanks-md

Articles

Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer: Part 2

Alan W. Partin, MD, PhD;Gerald E. Hanks, MD;Eric A. Klein, MD;Judd W. Moul, MD;William G. Nelson, MD, PhD;Howard I. Scher, MD

September 1st 2002

Despite the impact of prostate-specific antigen (PSA) testing on the detection and management of prostate cancer, controversy about its usefulness as a marker of disease activity continues. This review, based on a

Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer: Part 1

Alan W. Partin, MD, PhD;Gerald E. Hanks, MD;Eric A. Klein, MD;Judd W. Moul, MD;William G. Nelson, MD, PhD;Howard I. Scher, MD

August 1st 2002

Spectroscopy in Prostate Cancer: Hope or Hype?

Gerald E. Hanks, MD

November 1st 2001

Clinical applications of image-based radiation therapy for the study of prostate cancer have expanded significantly over the past years. The results of recent studies of magnetic resonance imaging (MRI) combined with magnetic

Evidence for Cure of ‘Young’ Men With Prostate Cancer

Gerald E. Hanks, MD;Alexandra L. Hanlon, PhD;Eric M. Horwitz, MD

May 1st 2001

A study was undertaken to evaluate the question of cure in "young" men with prostate cancer treated by external-beam radiation. Results in young men (£ 65 years) were compared to older men. Biochemical freedom from failure was examined to 10 years’ follow-up, and hazard functions for failure vs time were reported. Results show that prostate cancer patients are cured by external-beam radiation and that there is no difference in results for young or older men. Few failures occur after 5 years’ follow-up and the percentage cured is similar to that with prostatectomy, with much less morbidity. Appropriate dose is necessary to optimize outcome. [ONCOLOGY 15(5):563-574, 2001]

Prostate Cancer Risk Assessment Program

Deborah Watkins Bruner, RN, MSN;Agnes Baffoe-bonnie, MD, PhD;Suzanne Miller, PhD;Michael Diefenbach, PhD;James V. Tricoli, PhD;Mary Daly, MD, PhD;Wayne Pinover, DO;Sherry Campbell Grumet, MA;Eric Ross, PhD;Andrew Balshem, MD;Paul F. Engstrom, MD;Gerald E. Hanks, MD;Iila Mirchandani, MD

March 1st 1999

Prostate cancer is the most common form of cancer (except skin cancer) in men. Several factors have been associated with an increased risk for prostate cancer, including age, ethnicity, family history, lifestyle, and

Consensus Statement

Gerald E. Hanks, MD

November 1st 1997

In Session I of the First Sonoma Conference on Prostate Cancer, a critical concern in prostate cancer management was addressed: improving the pretreatment prediction of patients’ outcomes in localized prostate cancer.

The Prostate Cancer Intervention Versus Observation Trial (PIVOT)

Gerald E. Hanks, MD

August 1st 1997

As described by Wilt et al in their review, the Prostate Cancer Intervention Versus Observation Trial (PIVOT) is asking very important questions about the effect of surgical treatment vs observation, with delayed androgen deprivation available to both groups, in patients with localized prostate cancer. Clinicians who have suffered with the old Uro-Oncology Trial comparison of prostatectomy vs radiation hope that PIVOT provides answers rather than confusion.